Clinical Trials
9 trialsNCT03872388 2024-10-02
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02658812 2023-01-25
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03184558 2021-11-09
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Phase 2 Terminated
NCT02892734 2020-07-16
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Northwestern University
Phase 2 Terminated
NCT02389764 2019-07-17
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00118053 2013-11-20
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00343512 2012-04-27
Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00162812 2008-07-18
TOP
Jules Bordet Institute
Phase 2 Terminated